Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care | Biomarker Commons
Links shared publicly online about this topic.
- 13total visits
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care | Biomarker Commons
Precision Therapeutics, Inc. has recently expanded their BioSpeciFx product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision's approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test.
View full resource at biomarkercommons.org
Most Recently Shared on January 25, 2012 at 11:00 am By:
Advertisement
